Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BCY LifeSciences has signed an agreement with Align Pharmaceuticals to undertake further development and the marketing of DCF 987, a compound currently being developed for respiratory conditions such as cystic fibrosis.
Subscribe to our email newsletter
In 2004, BCY announced the results from a phase II clinical study which led to the agreement with Align.
The agreement provides for the continued development of DCF 987 with the initial focus remaining on cystic fibrosis (CF). It includes industry-standard upfront and milestone payments as well as royalty payments when DCF 987 is commercialized.
“We are very pleased to have DCF 987 as the first product in our portfolio,” commented Bill Collins, president and CEO of Align. “We are excited about its potential and look forward to taking the compound into clinical trials and on to the market.”
Lorne Meikle, BCY’s president and CEO commented, “The agreement validates our phase II results and means that if further clinical development is successful, patients suffering from CF and other respiratory disorders will have a new hope for managing their condition. This is truly a good news event for the patients, our partners and our shareholders.”